Latest Conference Articles

Richard Gray on a Longer Duration of Tamoxifen

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Dr. Brose on Sorafenib in RAI-Resistant Thyroid Cancer

Marcia Brose, MD, PhD, from the Abramson Cancer Center at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.

GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma

Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.

Dr. Heinemann Reviews the FIRE-3 Trial Results

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

Partners of HPV-Positive Oropharyngeal Cancer Patients Not at Increased Risk of HPV Infection or Oral Cancer

Patients with human papilloma virus–positive oropharyngeal cancer and their spouses may find some reassurance in a study that found that partners are no more likely to be infected by HPV than the general population.

Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer

An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.

Dr. Tewari on Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari, MD, from the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.

Cetuximab OS Results Top Bevacizumab in mCRC

Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.

Nivolumab Delivers Enduring Benefits in Advanced Melanoma

Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.

Dr. Sznol Describes Nivolumab in Advanced Melanoma

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

Dr. D'Souza on Spouses of HPV-Positive Patients

Gypsyamber D‘Souza, PhD, MPH, MS, from Johns Hopkins University, discusses the prevalence of oral HPV infections in the spouses of patients with HPV-positive oropharyngeal cancer.

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.

ASCO Highlights Put Variety in Spotlight

New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.

Dr. O'Shaughnessy on Everolimus in Breast Cancer

Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.

ASCO Opens 49th Annual Meeting Urging More Federal Funding for Research

The American Society of Clinical Oncology kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US biomedical research funding.

Dr. Pazdur on Breakthrough Designation Requirements

Richard Pazdur, MD, from the FDA's Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.

Combining Ipilimumab and Nivolumab Shows Promise in Advanced Melanoma

Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.

High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer

Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.

New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukemia

The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.

Adjuvant Surveillance Effective in Early-Stage Seminoma

Active surveillance following radical orchiectomy is an effective treatment strategy for men with stage I seminoma.

Follow-Up Scans Do Little to Detect Relapse of Diffuse Large B-Cell Lymphoma

Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.

In Treating Locally Advanced NSCLC, More Radiotherapy Is Not Better

Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.

Early Results Robust for New PD-L1 Immunotherapy Agent

An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.

Dramatic Shortage of Urologists on Horizon

An estimated 16,000 urologists will be needed to provide specialty care by 2025, but estimates of the number of urologists likely to be in practice at that time range between 6800 and 7400.

AUA Offers Evidence-Based Guide For Sequencing CRPC Therapies

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

AUA Abstract Roundup

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

Use of Expectant Management Lags in Prostate Cancer

Expectant management, which includes active surveillance and watchful waiting, is widely underused in the treatment of prostate cancer in the United States.

2013 American Urological Association Annual Meeting

The 108th American Urological Association (AUA) Annual Meeting is being held at the San Diego Convention Center from May 4 - 8, 2013, and features research, guideline updates, and the latest advances in urologic medicine.

Dr. Slovin on Prostate Cancer Immunotherapy Evolution

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.